BioSpace News Archive

Comments on social media provide a glimpse at the deep divide in trust of public health agencies, and now a new survey demonstrates the breadth of that distrust.

The Rare Disease Company Coalition’s 10 founding members have brought 22 treatments to market and currently have more than 160 rare disease programs in the works.

Shares of Heron Therapeutics climbs after it announced the U.S. FDA approved its non-opioid drug for extended pain relief following some surgeries.

Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.

Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress.

SANUWAVE Health, Inc., a leading provider of next-generation wound care products, has engaged international investor relations specialists MZ Group to lead a comprehensive strategic investor relations and financial communications program across all key markets.

Recognition marks fourth consecutive year as top-ranked Phase I provider to work with; Company ranked among top-two global CROs for Service Provider Leadership, Familiarity, Use and Preference in Phase I

Medtronic plc and the Medtronic Foundation announced an additional $3M USD for COVID-19 relief efforts – a combination of financial resources, personal protective equipment donations, and Medtronic employee engagement – focused on underserved areas of India, Brazil, the United States, and other global regions.

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present at the UBS Global Healthcare Virtual Conference on Tuesday, May 25 at 8 a.m. Eastern Time.

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that it will sponsor a symposium presenting the latest long-term clinical data on the Reducer™ (“Reducer”), highlighting its easy integration into current cardiovascular and microvascular disease treatments.